Our DNA
Cell & Gene Collaborative provides an informal, virtual setting for manufacturing professionals to meet their peers, brainstorm, and share their biggest learnings. Think “fire-side chat” meets “15-people-or-less video call with colleagues”— all questions answered, no hand-raising necessary.
Several times a year, Cell & Gene Collaborative Director Anna Rose Welch sits down to moderate an invite-only discussion between members of the cell and gene therapy and/or RNA therapeutics manufacturing community.
Whether it be a moderated discussion between Cell & Gene Collaborative’s Director Anna Rose Welch and a specific manufacturing subject matter expert, or a community-led “ask the manufacturing exec anything” Q&A session, these invite-only conversations reveal the biggest themes, challenges, and best-business practices impacting the day-to-day evolution of the advanced therapies manufacturing paradigm.
For a list of last season’s discussions, please see below.
Join the discussion today!
2021-2022 Collaborative Conversations |
|
A Closer Look Into USP/NIST/NIIMBL’s AAV Quality CollaborationA discussion with Fouad Atouf, VP Global Biologics—Science & Standards, US Pharmacopeia Related resource: |
Exploring Best Communication Practices Between C-Suite & CMC/Manufacturing TeamsA discussion with Mark Gergan, CEO, Poseida Therapeutics Related resources: |
|
|
|
Making Sense of CGT ComparabilityA discussion with Mo Heidaran, Head of Translational & Regulatory Strategy, GC Therapeutics |
mRNA Scale-Up: Lessons Learned From The Great mRNA Vaccine RushA discussion with Qian Ruan, VP of Tech Ops and Manufacturing, Arcturus Therapeutics |
|
|
|
Developing Your CGT Technical & Outsourcing StrategyA discussion with Paul McCormac, CTO, LEXEO Therapeutics Related resource: |
USP’s mRNA Quality Guidelines: Unpacking These First—And Future—Steps Toward Understanding The mRNA Drug SubstanceA discussion with Fouad Atouf, VP Global Biologics—Science & Standards, US Pharmacopeia |
|
|
|
2023 CGT Outlook: Analyzing Our Progress Toward Greater Manufacturing StandardizationA discussion with Katy Spink, COO, Dark Horse Consulting Related resource: |
2023 mRNA Outlook: What Challenges Are —Or Will Be — Keeping Manufacturing Experts Up At Night?A Discussion with Gloria Lam & Carlos Julia Figueras, PA Consulting |
CGT Outsourcing: The Current “Health” of Partnering, Capacity, & Platform DevelopmentA discussion with Joseph Graskemper, director, external manufacturing and supply, Solid Bioscience, & Adam Haskett, head of external manufacturing, CARGO Therapeutics |
|
Join Our Collaborative!
For eligibility criteria or more information, contact Anna Rose Welch by email or 814-897-9000 x253.